Clinical trial
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute…
NCT00385736 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00385736 |
|---|---|
| Title | Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis |
| Official title | A Multicenter, Randomized, Double-blind Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Biological |
| Interventions | adalimumab, placebo |
| Enrollment | 576 |
| Start date | Nov 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Mar 1, 2010 |
| First posted | Oct 11, 2006 |
| Last update posted | Apr 11, 2011 |
| Countries | Austria, Belgium, Canada, Czechia, Germany, Hungary, Italy, Netherlands, Poland, Puerto Rico, Slovakia, Sweden and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: